

CURRICULUM VITAE

Name: Athanasia Mouzaki

Address at work: Laboratory of Immunohematology, Division of Hematology, Dpt. of Internal Medicine, Medical School, University of Patras, Patras, GR-26500, Greece.

E-mail: mouzaki@upatras.gr / athanasia.mouzaki@gmail.com

<https://www.med.upatras.gr/index.php?r=faculty/view&id=200&lang=en>

Education:

1977: High School Diploma (2nd Lyceon for Girls, Patras, GR).

1979: General Certificates of Education (GCEs) in Chemistry, Physics, Mathematics and English (Cambridge Board, UK).

1983: Bachelor's degree (B.Sc. with Honors) in Biological Sciences (Major: Physiology, Specialization: Cellular Toxicology) (University of Plymouth, UK).

Diploma thesis: "Response of the lymphoid organs of the laboratory mouse to Plasmodium yoelli infection".

1985: Master's degree (MSc.) in Biological Sciences (Immunology) (University of Salford, UK).

MSc thesis: "Gasterosteus aculeatus, Linnaeus: The lymphoid system, diseases and ecological correlates".

1988: Doctor of Philosophy (Ph.D.) (University of Salford, UK & Free University of Berlin, DE).

Ph.D. thesis: "The rat receptor for Interleukin-2".

Positions/Teaching appointments:

1983-1985: Part-time lecturer and laboratory demonstrator, Laboratory of Immunology, University of Salford, Greater Manchester, UK.

1985-1987: Research assistant, Institute of Immunology, Medical School, Free University, Klinikum Steglitz, Berlin, DE.

1987-1990: Assistante post-doctorante, Dpt. of Molecular Biology, University of Geneva, Geneva, CH.

1991-1992: Assistante post-doctorante, Div. of Hematology, Medical School, University Hospital, Geneva, CH.

1992-1995: Maitre Assistante, Div. of Hematology, Medical School, University Hospital, Geneva, CH.

1995-1997: Lecturer of Laboratory Hematology & Transfusion Medicine, Medical School, University of Patras, Patras, GR.

1997-2003: Assistant Professor of Laboratory Hematology & Transfusion Medicine, Medical School, University of Patras, Patras, GR.

2003-2009: Associate Professor of Laboratory Hematology & Transfusion Medicine, Division of Hematology, Dpt. of Internal Medicine, Medical School, University of Patras, Patras, GR.

2009-now: Professor of Laboratory Hematology & Transfusion Medicine, Division of Hematology, Dpt. of Internal Medicine, Medical School, University of Patras, Patras, GR.

Teaching:

To medical students: Main courses: The analysis and interpretation of blood tests, the lymphopoietic system, the pathogenesis of autoimmune diseases. Elective courses: Introduction to Laboratory Hematology, Immunohematology.

To post-graduate students in 3 post-graduate courses (for a Master's degree): Main courses: Immunology-clinical/cellular/molecular, research methodology, analysis of the scientific literature, how to write scientific articles. Elective courses: Laboratory training in Immunohematology methods.

Clinical duties:

Responsible for the Laboratory of the Hellenic Center for Disease Control and Prevention in Patras, Greece. The laboratory measures the HIV viral load and performs HLA-B*5701 typing and genotypic analyses to determine drug-resistance and other mutations of individuals with established HIV-1

infection attending the Division of Infectious Diseases of the University Hospital, Patras, Greece. Responsible for the investigation of the prevalence of HIV-1 subtypes in southwestern Greece.

Responsible for the Laboratory of Molecular Diagnosis of Infectious Agents, Medical School, University of Patras, which runs molecular diagnostic tests for the 6th Health District of Greece for the detection of viruses such as SARS-CoV-2, Monkeypox, Influenza A and B, RSV.

Administrative duties:

Established the research laboratory of Immunohematology and participated in the setting and start-up of common research facilities of the Medical School, University of Patras.

Member (1/5) of a committee appointed by the Health Ministry to design the application of molecular testing for viruses in the Blood Centers of Greece.

Established the Laboratory of Molecular Diagnosis of Infectious Agents of the Medical School, University of Patras.

Member (1/3) of a committee that runs the quality control of the post-graduate course "Biomedical Sciences" of the Medical School, University of Patras.

Member of the General Assembly of the Medical School, University of Patras, for the acad. years 1995-96, 1998-99, 2001-02, 2006-07, 2011-12, 2015-24.

Member (since 1995) of a committee that organizes and supervises the laboratory courses of the students of the Medical School, University of Patras. Head of the committee since 2009.

Vice President of the post-graduate program Medicinal Chemistry, Biological Chemistry (Dpt. of Chemistry and Medical School, University of Patras) for acad. years 2018-26.

Member of electoral boards for the election of faculty in Hematology and Immunology in all Greek Universities and the Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

President of the post-graduate course "Biomedical Sciences" of the Medical School, University of Patras for acad. years 2024-26.

Member of **11** Scientific Societies. Founding member of the Hellenic Society of Neuroimmunology.

Main research interests:

IL-2, HIV-1: Study the transcriptional regulation of the IL-2 gene and the virus HIV-1 in naive, memory and regulatory T helper lymphocytes, with emphasis on genomic conflict.

T-cells & Cytokines: Characterization of effector and regulatory T-cell populations in autoimmune and inflammatory diseases.

Identification of errors in the transcriptional regulation of cytokine genes in effector and regulatory T-cells from patients suffering from autoimmune diseases.

Development of antigen-specific T cells for immunotherapy in cancer and autoimmune diseases.

Leptin: Role of leptin and its receptor in autoimmune and hematologic diseases.

Microbiome and immune cells: Molecular interaction in the pathogenesis of autoimmune and inflammatory diseases and cancer.

Research grants:

Recipient of 35 research grants (PI or co-PI) amounting to 5M €. My share of these grants amounted to 1,451,374 €.

Supervisor of post-graduate students:

Supervisor in 18 Ph.D. Theses (15 completed)

Supervisor in 44 MSc. theses (42 completed)

Supervisor in 14 Diploma projects (13 completed).

Co-supervisor and member of the examination committees of 77 Ph.D. theses (65 completed) and 20 MSc. theses (19 completed).

Current members of research laboratory:

Post-doctoral scientists: 1

Post-graduate students: 4

Diploma students: 1

Scientific meetings - Participation in 128 international and national scientific meetings (invited in 91).

International Scientific Publications:

Papers: **161**

Chapters in books: **3**

Abstracts: **156**

National Scientific Publications:

Papers: **5**

Chapters in books or proceedings volumes: **12**

Abstracts: **98**

Publication metrics (JOURNAL CITATION REPORTS-2023):

IF: mean: **5.6** / cumulative: **738.6**

IF of journals AM is 1st, 2nd, or last author: mean: **6.7** / cumulative: **521.8**

Citations: **5,152** / h-index: **38** / i10 index: **97**

see also:

https://scholar.google.gr/citations?hl=en&user=Gr9XNVMAAAAJ&view_op=list_works&sortby=pubdate

Reviewer for:**JOURNALS:**

1. Acta Haematologica
2. Advances in Research
3. American Journal of Physiology
4. AIMS Allergy and Immunology
5. Anti-Cancer Agents in Medicinal Chemistry
6. Antibodies
7. Archivum Immunologiae et Therapiae Experimentalis
8. Autoimmunity Reviews
9. Biomedicines
10. Biomolecules
11. Bioorganic Chemistry
12. Blood
13. Blood Transfusion
14. BMC Hematology
15. BMC Immunology
16. BMC Research Notes
17. Brain Sciences
18. British Journal of Medicine and Medical Research
19. British Journal of Pharmaceutical Research
20. Cancers
21. Cell Biology International
22. Cells

23. Cellular & Molecular Immunology
24. Clinica Chimica Acta
25. Clinical Immunology
26. Clinical Risk Management
27. Current Immunology Reviews
28. Current Issues in Molecular Biology (CIMB)
29. Current Medical Literature – Multiple Sclerosis
30. Current Medicinal Chemistry
31. Current Opinion in Investigational Drugs
32. Current Pharmaceutical Design
33. Cytokine
34. Endocrine, Metabolic & Immune Disorders - Drug Targets
35. European Journal of Clinical Investigation
36. European Journal of Dermatology
37. European Journal of Neurology
38. European Journal of Pediatrics
39. Food and Chemical Toxicology
40. Frontiers in Cellular and Infection Microbiology
41. Frontiers in Immunology
42. Frontiers in Medicine
43. Frontiers in Nutrition
44. Future Neurology
45. Genes and Immunity
46. Haema
47. Haematologica/The Haematology Journal
48. Heliyon
49. Hormones
50. Immunological Investigations
51. ImmunoTargets and Therapy
52. International Aquatic Research
53. International Blood Research & Reviews
54. International Immunopharmacology
55. International Journal of Laboratory Haematology
56. International Journal of Medicine and Medical Sciences
57. International Journal of Molecular Sciences
58. International Journal of Nanomedicine
59. IUBMB Life
60. Journal of Advanced Research
61. Journal of Clinical Immunology
62. Journal of Clinical Medicine
63. Journal of Hematology & Oncology
64. Journal of Immunological Methods
65. Journal of Immunological Sciences
66. Journal of Immunology
67. Journal of Leukocyte Biology
68. Journal of Medicinal Chemistry
69. Journal of Neuroimmunology
70. Journal of Neurology & Neuromedicine,

71. Journal of Pediatric Endocrinology and Metabolism
72. Journal of Thrombosis and Haemostasis
73. JSM Neurosurgery and Spine
74. Letters in Drug Design & Discovery
75. Mediators of Inflammation
76. Medicinal Chemistry
77. Molecular Immunology
78. Neuroimmunomodulation
79. Pharmaceutics
80. PLOS ONE
81. Recent Patents on Inflammation & Allergy Drug Discovery
82. Scientific Reports
83. The Open Autoimmunity Journal
84. The Open Immunology Journal
85. The Open Respiratory Medicine Journal
86. Therapeutic Advances in Chronic Disease
87. Therapeutics and Clinical Risk Management
88. Thrombosis and Haemostasis
89. Transfusion Medicine and Hemotherapy

SCIENTIFIC BOARDS:

Medical Research Council, UK,

The Netherlands Organization for Research and Development,

The Health Research Board in Ireland,

The Research Promotion Foundation of Cyprus,

Education and Health Research Boards in Greece (IKY, KeSY, grants co-funded by the Greek government and the European Social Fund).

Editorial duties:

Guest Editor for an issue of Current Topics in Medicinal Chemistry (Bentham Science Publishers Ltd.). Title of issue: «Immunomodulators in Medicinal Chemistry and Drug Discovery». [Vol.6, number 16, pp.1655-1798, 2006]

Responsible for the preparation of the Greek Edition of the textbook “Lippincott’s Illustrated Reviews: Immunology”, 2nd Edition by T. Doan, R. Melvold, S. Viselli, C. Waltenbaugh, 2014 (ISBN: 978-960-394-985-2).

Section Editor, International Journal of Molecular Sciences, MDPI

Topic Editor, International Journal of Molecular Sciences, MDPI, Section: Molecular Immunology

Member of the Editorial Board, Biomolecules, MDPI

Member of the Editorial Board, International Journal of Molecular Sciences, MDPI

Topic Editor, Frontiers in Immunology

Associate Editor, Frontiers in Immunology

Associate Editor, Achaiki Iatriki [Official Journal of The Medical Society of Western Greece and Peloponnesus (IEDEP)]

Chapters in Books:

Mouzaki A, Kupiec-Weglinski JW, Volk HD, Diamantstein T. 1989. In vivo action of anti-interleukin 2 receptor monoclonal antibodies. In: «Cellular Basis of Immune Modulation», pp.547-550, JG Kaplan, DR Green (Eds.), AR Liss Inc., New York.

Chatzantoni K, Mouzaki A. 2009. Immunomodulation in the nervous and vascular systems during inflammation and autoimmunity; the role of T regulatory cells. In: “Neurovascular Medicine: Pursuing

Cellular Longevity for Healthy Aging”, K. Maiese (Ed.), Oxford University Press, New York. Chapter 14, pp. 345-366.

Chatzantoni K, Mouzaki A. 2010. Stem cell transplantation to treat severe refractory autoimmune diseases. In: “New Insights in Hematopoietic Cell Transplantation”, A. Spyridonidis, I. Sakellari (Eds.), Research Signpost, Kerala. Chapter 15, pp. 271-284.

Papers:

1. Diamantstein T, Osawa H, Mouzaki A, Josimovic-Alasevic O. 1986. Regulation of interleukin-2 receptor expression and receptor release. *Mol. Immunol.*, 23(11):1165-1172. doi: 10.1016/0161-5890(86)90147-1.
2. Mouzaki A, Volk HD, Osawa H, Diamantstein T. 1987. Blocking of interleukin 2 (IL2) binding to the IL2 receptor is not required for the in vivo action of anti-IL2 receptor monoclonal antibody (mAb). I. The production, characterization and in vivo properties of a new mouse anti-rat IL2 receptor mAb that reacts with an epitope different to the one that binds to IL2 and the mAb ART-18. *Eur. J. Immunol.*, 17(3):335-341. doi: 10.1002/eji.1830170306.
3. Mouzaki A, Osawa H, Diamantstein T. 1987. An ELISA that detects cell-associated and released rat IL-2 receptors in a soluble form. *J. Immunol. Methods*, 100(1-2):243-248. doi: 10.1016/0022-1759(87)90195-5.
4. Mouzaki A, Diamanstein T. 1987. Four epitopes on the rat 55 kDa subunit of the interleukin 2 receptor as defined by newly developed monoclonal antibodies. *Eur. J. Immunol.*, 17(11):1661-1664. doi: 10.1002/eji.1830171123.
5. Di Stefano R, Mouzaki A, Araneda D, Diamanstein T, Tilney NL, Kupiec-Weglinski JW. 1988. Anti-interleukin 2 receptor monoclonal antibodies spare phenotypically distinct T suppressor cells in vivo and exert synergistic biological effects. *J. Exp. Med.*, 167(6):1981-1986.
6. Kupiec-Weglinski JW, Hahn HJ, Kirkman L, Volk HD, Mouzaki A, Di Stefano R, Tellides G, Dallman M, Morris PJ, Strom TB, Tilney NL, Diamantstein T. 1988. Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy. *Transplantat. Proc.*, 20(2):207-216.
7. Stünkel KG, Theisen P, Mouzaki A, Diamantstein T, Schlumberger HD. 1988. Monitoring of interleukin-2 receptor (IL-2R) expression in vivo and studies on an IL-2R-directed immunosuppressive therapy of active and adoptive adjuvant-induced arthritis in rats. *Immunology*, 64(4):683-689.
8. Diamanstein T, Mouzaki A, Osawa H, Volk HD, Hahn HJ, Kirkman RL, Strom TB, Tilney NL, Kupiec-Weglinski JW. 1988. Inhibition of allograft rejection and organ-specific autoimmune disease by anti-interleukin-2 receptor (IL2R)-targeted immunotherapy. The action of anti-IL2R monoclonal antibodies and synergistic effect of cyclosporin A. *Dev. Biol. Stand.*, 69:177-184.
9. Herrmann T, Josimovic-Alasevic O, Mouzaki A, Diamantstein T. 1989. Demonstration of two distinct forms of the released low affinity type rat interleukin 2 receptor. *Immunology*, 66(3):384-387.
10. Bartok I, Erdei A, Mouzaki A, Osawa H, Szolosi J, Eigentler A, Diamantstein T, Dierich M, Gergely J. 1989. Interaction between C3 and IL-2; inhibition of C3b binding to CR1 by IL-2. *Immunol. Letters*, 21(2):131-137.
11. Mouzaki A, Weil R, Muster L, Rungger D. 1991. Silencing and trans-activation of the mouse IL-2 gene in *Xenopus* oocytes by proteins from resting and mitogen-induced primary T-lymphocytes. *EMBO J.*, 10(6):1399-1406.
12. Tucci A, Mouzaki A, James H, Bonnefoy JY, Zubler RH. 1991. Are cord blood B cells functionally mature? *Clin. Exp. Immunol.*, 84(3):389-394.
13. Mouzaki A, Zubler RH, Doucet A, Rungger D. 1992. Trans-active factors controlling the IL-2 gene in adult human T-cell subsets. *Mediat. Inflamm.*, 1(1):33-37.
14. Mouzaki A, Dai Y, Weil R, Rungger D. 1992. Cyclosporin A and FK506 prevent the derepression of the IL-2 gene in mitogen-induced primary T lymphocytes. *Cytokine*, 4(2):151-160.
15. Hentsch B, Mouzaki A, Pfeuffer I, Rungger D, Serfling E. 1992. The weak, fine-tuned binding of ubiquitous transcription factors to the IL-2 enhancer contributes to its T cell-restricted activity. *Nucleic Acids Res.*, 20(11):2657-2665.
16. Mouzaki A, Rungger D, Tucci A, Doucet A, Zubler RH. 1993. Occurrence of a silencer for the interleukin-2 gene in naïve but not memory resting T helper cells. *Eur. J. Immunol.* 23(7):1469-1474.

17. Mouzaki A, Rungger D. 1994. Interleukin 2 gene regulation at the P_ud (NFAT) promoter element: The complex situation in primary T lymphocytes. *Proc. Molec. Biol. Hematopoiesis*, 3:475-486.
18. Mouzaki A, Rungger D. 1994. Properties of transcription factors regulating interleukin 2 gene transcription through the NFAT binding site in untreated or drug-treated naïve and memory T helper cells. *Blood*, 84(8):2612-2621.
19. Mouzaki A, Zubler RH. 1995. Regulation de la transcription du gene de l'interleukine-2 dans les lymphocytes B. *Swiss Med. Wkly*, 125(9):395-399.
20. Mouzaki A, Serfling E, Zubler RH. 1995. Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor- κ B. *Eur. J. Immunol.*, 25(8):2177-2182.
21. Mouzaki A, Matthes T, Miescher PA, Beris P. 1995. Polyclonal hypergammaglobulinaemia in a case of B cell Chronic Lymphocytic Leukaemia: The result of IL-2 production by the proliferating monoclonal B cells? *Br. J. Haematol.*, 91(2):345-349.
22. Mouzaki A, Kindler V, Browers N, Doucet A, Melachrinou M, Kyrtsionis MC, Kallinikou-Maniatis A. 1996. Cytokine gene expression in a case of B-cell Chronic Lymphocytic Leukaemia (B-CLL) with an unusual expansion of T cells at presentation. *Proc. Molec. Biol. Hematopoiesis*, 5:237-246.
23. Kyrtsionis MC, Repa C, Dedoussis GVZ, Mouzaki A, Simeonidis A, Stamatelou M, Maniatis A. 1998. Serum transforming growth factor- β 1 (TGF- β 1) in patients with multiple myeloma (MM). *Med. Oncol.*, 15(2):124-128.
24. Mouzaki A, Dionyssopoulou H, Sotiropoulou G, Cordopatis P, Slootstra J, Puijk W, Meloen R, Maniatis A. 1999. Synthetic peptides as putative therapeutic agents in transplantation medicine: Identification of epitopes on the extra cellular domain of the beta chain of the interleukin-2 receptor. *Biomed. & Health Res. Ser.*, 22:181-193.
25. Dedoussis GVZ, Mouzaki A, Theodoropoulou M, Menounos P, Kyrtsionis MC, Karameris A, Maniatis A. 1999. Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line. *Exp. Cell Res.*, 249(2):269-278.
26. Kyrtsionis MC, Mouzaki A, Maniatis A. 1999. Mechanisms of polyclonal hypogammaglobulinemia in multiple myeloma. *Med. Oncol.*, 16(2):73-77.
27. Dionyssopoulou E, Mouzaki A, Slootstra J, Puijk W, Meloen R, Cordopatis R, Sotiropoulou G. 2000. Synthetic peptides as putative therapeutic agents in transplantation medicine: Application of PEPSCAN to the identification of functional sequences on the extracellular domain of the Interleukin-2 receptor beta chain (IL-2R β). *J. Immunol. Methods*, 241(1-2):83-95.
28. Mouzaki A, Doucet A, Mavroidis E, Muster L, Rungger D. 2000. A repression-derepression mechanism regulating the transcription of human immunodeficiency virus type 1 in primary T cells. *Mol. Med.*, 6(5):377-390.
29. Karakantza M, Mouzaki A, Theodoropoulou M, Bussel JB, Maniatis A. 2000. Th1 and Th2 cytokines in a patient with Evans' syndrome and profound lymphopenia. *Br. J. Haematol.*, 110(4):968-970.
30. Tselios T, Daliani I, Deraos S, Thymianou S, Matsoukas E, Troganis A, Gerothanassis I, Mouzaki A, Mavromoustakos T, Probert L, Matsoukas I. 2000. Treatment of experimental allergic encephalomyelitis (EAE) by a rationally designed cyclic analogue of myelin basic protein (MBP) epitope 72-85. *Bioorg. Med. Chem. Lett.*, 10(24):2713-2717.
31. Theodoropoulou M, Karakantza M, Maniatis A, Mouzaki A. 2000. Cytokine gene expression in a case of Evan's syndrome. *Proc. Eur. Fed. Immunol. Soc.*, 1:287-293.
32. Leotsinidis M, Theodoropoulou M, Alexopoulos A, Chatzantoni K, Farri-Kostopoulou E, Mouzaki A. 2000. Leptin and interleukin-2 in babies. *Proc. Eur. Fed. Immunol. Soc.*, 1:281-285.
33. Doucet A, Mouzaki A. 2000. HIV-1 regulation in peripheral blood T-cells. *Proc. Eur. Fed. Immunol. Soc.*, 1:385-391.
34. Xagoraris I, Zikos P, Karakantza M, Maniatis A, Mouzaki A. 2000. Apoptosis in multiple myeloma cells. *Proc. Eur. Fed. Immunol. Soc.*, 1:113-119.
35. Xagoraris I, Paterakis G, Zolota B, Zikos P, Maniatis A, Mouzaki A. 2001. Expression of granzyme B and perforin in multiple myeloma. *Acta Haematol.*, 105(3):125-129.
36. Kakkos SK, Mouzaki A, Vagianos CE. 2001. Modifications of the immune system caused by the cestode *Echinococcus granulosus*. *Ann. Gastroenterol.*, 14(2):91-98.
37. Tselios T, Apostolopoulos V, Daliani I, Deraos S, Grdadolnik S, Mavromoustakos T, Melachrinou M, Thymianou S, Probert L, Mouzaki A, Matsoukas I. 2002. Antagonistic effects of human MBP₈₇₋₉₉ altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation. *J. Med. Chem.*, 45(2):275-283.

38. Thymianou S, Chatzantoni K, Karakantza M, Tselios T, Papathanassopoulos P, Matsoukas JM, Mouzaki A. 2002. Effect of linear and cyclic peptide analogues of myelin basic epitope MBP72-85 on human T-cell activation. *Biomed. & Health Res.*, 55:241-250.
39. Mouzaki A, Theodoropoulou M, Gianakopoulos I, Vlaha V, Kyrtsonis MC, Maniatis A. 2002. Expression Patterns of Th1 and Th2 Cytokine Genes in Childhood Idiopathic Thrombocytopenic Purpura (ITP) at Presentation and their Modulation by Intravenous Immunoglobulin G (IVIg) Treatment; their Role in Prognosis. *Blood*, 100(5):1774-1779.
40. Panitsas F, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou G, Zoumbos NC, Maniatis A, Mouzaki A. 2004. Adult chronic idiopathic thrombocytopenia purpura (ITP) is the manifestation of a type-1 polarized immune response. *Blood*, 103(7):2645-2647.
41. Lekkou A, Karakantza M, Mouzaki A, Kalfarentzos F, Gogos CA. 2004. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. *Clin. Diagn. Lab. Immunol.*, 11(1):161-167.
42. Argyropoulos C, Nikiforidis GC, Theodoropoulou M, Adamopoulos P, Boubali S, Georgakopoulos TN, Paliogianni F, Papavassiliou AG, Mouzaki A. 2004. Mining microarray data to identify transcription factors expressed in naïve resting but not activated T lymphocytes. *Genes Immun.*, 5(1):16-25.
43. Karakantza M, Theodorou GL, Mouzaki A, Theodori E, Vagianos C, Maniatis A. 2004. In vitro study of the long-term effects of post traumatic splenectomy on cellular immunity. *Scand. J. Immunol.*, 59(2):209-219.
44. Chatzantoni K, Thymianou S, Papathanassopoulos P, Tselios T, Kalbacher H, Matsoukas J, Mouzaki A. 2004. Immunological profile of myelin basic protein (MBP) peptides. In: «Immunology 2004», pp.171-175, Medimond, Bologna (Italy). www.medimond.com
45. Argyropoulos C, Adamopoulos P, Georgakopoulos T, Chatzantoni K, Nikiforidis G, Mouzaki A. 2004. Identification of transcriptional repressors of HIV virus in naïve T lymphocytes using «wet» bioinformatics techniques. In: «Immunology 2004», pp.267-271, Medimond, Bologna (Italy). www.medimond.com
46. Chatzantoni K, Papathanassopoulos P, Gourzoulidou E, Mouzaki A. 2004. Leptin and its soluble receptor in plasma of patients suffering from remitting-relapsing multiple sclerosis (MS). In vitro effects of leptin on type-1 and type-2 cytokine secretion by peripheral blood mononuclear cells, T-cells and monocytes of MS patients. *J. Autoimmun.*, 23(2):169-177.
47. Parissi T, Chatzantoni K, Deraos S, Matsoukas I, Mouzaki A. 2004. Synthetic peptides mapping to epitopes of the extracellular domain of the IL-2 receptor (IL-2R) beta chain to inhibit T-cell activation. *Transplant. Proc.*, 36(6):1723-1727.
48. Mouzaki A, Tselios T, Papathanassopoulos P, Matsoukas I, Chatzantoni K. 2004. Immunotherapy for Multiple Sclerosis: Basic insights for new clinical strategies. *Curr. Neurovasc. Res.*, 1(4):325-340.
49. Karakantza M, Theodorou GL, Meimaris N, Mouzaki A, Ellul J, Andonopoulos AP, Maniatis A. 2004. Type-1 and Type-2 Cytokine-producing CD4+ and CD8+ Cells in Primary Antiphospholipid Syndrome (PAPS). *Ann. Hematol.*, 83(11):704-711.
50. Micheva I, Thanopoulou E, Michalopoulou S, Karakantza M, Kouraklis-Symeonidis A, Mouzaki A, Zoumbos N. 2004. Defective tumor necrosis factor alpha-induced maturation of monocyte-derived dendritic cells in patients with myelodysplastic syndromes. *Clin. Immunol.*, 113(3):310-317.
51. Panitsas FP, Mouzaki A. 2004. Effect of splenectomy on type-1/type-2 cytokine gene expression in a patient with adult idiopathic thrombocytopenic purpura (ITP). *BMC Blood Disord.*, 4(1):4.
52. Koutras AK, Makatsoris T, Paliogianni F, Kopsida G, Onyenadum A, Gogos CA, Mouzaki A, Kalofonos HP. 2004. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. *Oncology*, 67(2):179-182.
53. Matsoukas J, Apostolopoulos V, Kalbacher H, Papini A-M, Tselios T, Chatzantoni K, Biagioli T, Lolli F, Deraos S, Papathanassopoulos P, Troganis A, Mantzourani E, Mavromoustakos T, Mouzaki A. 2005. Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: Enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. *J. Med. Chem.*, 48(5):1470-1480.
54. Mouzaki A, Deraos S, Chatzantoni K. 2005. Advances in the treatment of autoimmune diseases; cellular activity, type-1/type-2 cytokine secretion patterns, and their modulation by therapeutic peptides. *Curr. Med. Chem.*, 12(13):1537-1550.
55. Mouzaki A. 2006. *Curr. Top. Med. Chem.*, 6(16):1655. EDITORIAL.

56. Chatzantoni K, Mouzaki A. 2006. Anti-TNF- α antibody therapies in autoimmune diseases. *Curr. Top. Med. Chem.*, 6(16):1707-1714.
57. Argyropoulos C, Mouzaki A. 2006. Immunosuppressive drugs in HIV disease. *Curr. Top. Med. Chem.*, 6(16):1769-1789.
58. Michalopoulou S, Micheva I, Karakantza M, Kouraklis-Symeonidis A, Mouzaki A, Zoumbos NC. 2006. Enhanced expression and inducibility of cytoprotective Heat Shock Proteins (Hsps) in the bone marrow of patients with Myelodysplastic Syndrome (MDS): correlation with disease progression. *Haematologica*, 91(12):1714-1716.
59. Leonidou L, Mouzaki A, Michalaki M, de Lastic AL, Kyriazopoulou V, Bassaris HP, Gogos CA. 2007. Cytokine production and hospital mortality in patients with sepsis-induced stress hyperglycemia. *J. Infect.*, 55(4):340-346.
60. Theodorou GL, Mouzaki A, Tsiftsis D, Apostolopoulou A, Mougou A, Theodori E, Vagianos C, Karakantza M. 2007. Effect of non-operative management (NOM) of splenic rupture versus splenectomy on the distribution of peripheral blood lymphocyte populations and cytokine production by T cells. *Clin. Exp. Immunol.*, 150(3):429-436.
61. Sgourou A, Karakantza M, Theodori E, Papadimitriou C, Theodorou GL, Davanos N, Thymianou S, Zoumbos NC, Mouzaki A. 2008. Procleix Ultrio transcription mediated amplification (TMA) vs serologic blood screening in southwestern Greece. *Transfus. Med.*, 18(2):104-111. doi: 10.1111/j.1365-3148.2008.00847.x
62. Theodorou GL, Marousi S, Ellul J, Mougou A, Theodori E, Mouzaki A, Karakantza M. 2008. Th1/Th2 cytokine expression shift in peripheral blood CD4⁺ and CD8⁺ T-cells of patients at the post-acute phase of stroke. *Clin. Exp. Immunol.*, 152(3):456-463. doi: 10.1111/j.1365-2249.2008.03650.x
63. Fourtounas C, Mouzaki A, Vlachojannis JG. 2008. Desensitization during renal transplantation. *NEJM*, 359(16):1731. doi: 10.1056/NEJMc081723
64. Papanastasiou AD, Chatzantoni K, Mouzaki A. 2008. Current therapeutic leads for the treatment of autoimmune diseases: stem cell transplantation and inhibition of post-translational modifications of autoantigens. *Exp. Opin. Drug Disc.*, 3(10):1255-1265. doi: 10.1517/17460441.3.10.1255
65. Deraos G, Chatzantoni K, Matsoukas M-T, Tselios T, Deraos S, Katsara M, Papathanasopoulos P, Vynios D, *Apostolopoulos V, *Mouzaki A, *Matsoukas J. 2008. Citrullination of linear and cyclic altered peptide ligands from Myelin Basic Protein (MBP87-99) epitope elicits a Th1 polarized response by T cells isolated from multiple sclerosis patients: implications in triggering disease. *J. Med. Chem.*, 51(24):7834-7842. doi: 10.1021/jm800891n. *senior authors
66. Charokopos N, Apostolopoulos N, Kalapodi M, Leotsinidis M, Karamanos N, Mouzaki A. 2009. Bronchial asthma, chronic obstructive pulmonary disease and NF- κ B. *Curr. Med. Chem.*, 16(7): 867-883.
67. Mania VM, Kallivokas AG, Malavaki C, Asimakopoulou AP, Kanakis J, Theocharis AD, Klironomos G, Gatzounis G, Mouzaki A, Panagiotopoulos E, Karamanos NK. 2009. A comparative biochemical analysis of glycosaminoglycans and proteoglycans in human orthotopic and heterotopic bone. *IUBMB Life*, 61(4):447-452. doi: 10.1002/iub.167
68. Katsoulidou A, Paraskevis D, Magiorkinis E, Moschidis Z, Haida C, Hatzitheodorou E, Varaklioti A, Karafoulidou A, Hatzitaki M, Kavallierou L, Mouzaki A, Andrioti E, Veneti C, Kaperoni A, Zervou E, Politis C, Hatzakis A. 2009. Molecular characterization of occult hepatitis B cases in Greek blood donors. *J. Med. Virol.*, 81(5):815-825. doi: 10.1002/jmv.21499
69. Mouzaki A, Panagoulas I, Dervilli Z, Zolota V, Spadidea P, Rodi M, Panitsas FP, Lagadinou E, de Lastic AL, Georgakopoulos T. 2009. Expression patterns of leptin receptor (OB-R) isoforms and direct in vitro effects of recombinant leptin on OB-R, leptin expression and cytokine secretion by human hematopoietic malignant cells. *Cytokine*, 48(3):203-211. doi: 10.1016/j.cyto.2009.07.006
70. Kyrtonis MC, Maltezas D, Koulrieris E, Zaroulis C, Tzenou T, Sachanas S, Bartzis V, Georgiou G, Dimou M, Siakavellas S, Vassilakopoulos TP, Angelopoulou MK, Koutra E, Mouzaki A, Pangalis GA, Panayiotidis P. 2010. Response to Bortezomib in refractory/relapsed multiple myeloma patients: A single center experience with discussion on specific issues. *APJOH*, 2(1):29-39.
71. Stoukas VS, Prousalis KP, Panagoulas I, Zarkadis IK, Mouzaki A. 2010. Postmortem redistribution of phenobarbital in a rat model. *Can. Soc. Forensic Sci. J.*, 43(1):1-8.
72. Fourtounas C, Dousdampanis P, Sakellarakis P, Rodi M, Georgakopoulos T, Vlachojannis JG, Mouzaki A. 2010. Different immunosuppressive combinations on T-cell regulation in renal

- transplant recipients. *Am. J. Nephrol.*, 32(1):1-9. doi: 10.1159/000313940
73. Mouzaki A, Koutsokera M, Dervilli Z, Rodi M, Kalavrizioti D, Dimisianos N, Matsoukas I, Papathanasopoulos P. 2010. Remitting-relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab. *Int. J. Gen. Med.*, 3:313-320. doi: 10.2147/IJGM.S13648
 74. Tsambaos D, Rodi M, Pasmazi E, Monastirli A, Papadaki H, Mouzaki A. 2011. Long-term Remission of Recurrent Herpes Labialis Following Topical Imiquimod Application on Distant Healthy Skin: A Clinical and Immunological Study. *Antivir. Ther.* 16(6):863-869. doi: 10.3851/IMP1793
 75. Dimitrakopoulos FID, Papadaki H, Antonacopoulou AG, Kottorou A, Gotsis AD, Scopa C, Kalofonos HP, Mouzaki A. 2011. Association of FoxP3 expression with non-small cell lung cancer. *Anticancer Res.*, 31(5):1677-1683.
 76. Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Korantzopoulos P, Tsianos EV. 2011. Serum IL-6 levels and cirrhosis-associated pulmonary hypertension. *Angiology*, 62(4):344-345. doi: 10.1177/0003319710396352
 77. Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Tsianos EV. 2011. Bacterial translocation attenuates the systemic hemodynamic improvement produced by Terlipressin in patients with cirrhosis. *Hepatology*, 54(2):743-744. doi: 10.1002/hep.24424
 78. Dimitropoulou D, Karanantza M, Tsamandas AC, Mouzaki A, Theodorou G, Gogos CA. 2011. T-lymphocyte subsets in peripheral blood and liver tissue of patients with chronic Hepatitis B and C. *In Vivo*, 25(5):833-840.
 79. Kalambokis GN, Mouzaki A, Rodi M, Tsianos EV. 2012. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia. *Liver Int.*, 32(3):467-475. doi: 10.1111/j.1478-3231.2011.02650.x
 80. Varvarigou AA, Thomas I, Rodi M, Economou I, Mantagos S, Mouzaki A. 2012. Respiratory distress syndrome (RDS) in premature infants is underscored by the magnitude of Th1 cytokine polarization. *Cytokine*, 58(3):355-360. doi: 10.1016/j.cyto.2012.03.005
 81. Kalambokis GN, Mouzaki A, Rodi M, Tsianos EV. 2012. Rifaximin for the prevention of spontaneous bacterial peritonitis. *World J. Gastroenterol.*, 18(14):1700-1702. doi: 10.3748/wjg.v18.i14.1700
 82. Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Korantzopoulos P, Tsianos EV. 2012. Circulating endotoxin and interleukin-6 levels are associated with Doppler-evaluated pulmonary vascular resistance in cirrhotic patients. *Hepatol. Int.*, 6(4):783-789. doi: 10.1007/s12072-011-9337-0
 83. Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Fotopoulos A, Xourgia X, Tsianos EV. 2012. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. *Clin. Gastroenterol. Hepatol.*, 10(7):815-818. doi: 10.1016/j.cgh.2012.02.025
 84. Mouzaki A, Panagoulas I, Raptis G, Farri-Kostopoulou E. 2012. Cord blood leptin levels of healthy neonates are associated with IFN- γ production by cord blood T-cells. *PLoS ONE*, 7(7):e40830. <http://dx.doi.org/10.1371/journal.pone.0040830>
 85. Dimitropoulou D, Karakantza M, Theodorou GL, Leonidou L, Assimakopoulos SF, Mouzaki A, Gogos CA. 2013. Serum cytokine profile in patients with hepatitis B e antigen-negative chronic active hepatitis B and inactive hepatitis B virus carriers. *World J. Gastrointest. Pathophysiol.*, 4(1):24-27. doi: 10.4291/wjgp.v4.i1.24
 86. de Lastic A, Rodi M, Mouzaki A. 2013. Th1/Th2/Th17 profile and T cell phenotype of an in vitro antigen presentation system in response to DC functionality, IL-2 and IGF-1 presence. In: «Immunology 2013», pp.17-19 www.medimond.com
 87. Lagadinou M, Solomou EE, Mouzaki A, Gogos CA. 2014. Alterations in cytokine measurements in ascitic fluid of cirrhotic patients with and without spontaneous bacterial peritonitis. *Clin. Hepatol. Hepat. Rep.*, 1:1. <http://dx.doi.org/10.7243/2055-088X-1-1>.
 88. Lekkou A, Mouzaki A, Siagris D, Ravani I, Gogos CA. 2014. Serum lipid profile, cytokine production and clinical outcome in patients with severe sepsis. *J. Crit. Care*, 29:723-727. doi: 10.1016/j.jcrc.2014.04.018
 89. Kostopoulou ON, Kouvela EC, Magoulas GE, Garnelis T, Panagoulas I, Rodi M, Papadopoulos G, Mouzaki A, Dinos GP, Papaioannou D, Kalpaxis DL. 2014. Conjugation with polyamines enhances the antibacterial and anticancer activity of chloramphenicol. *Nucleic Acids Res.*, 42(13):8621-8634. doi: 10.1093/nar/gku539

90. Dimisianos N, Rodi M, Kalavrizioti D, Georgiou LV, Papathanasopoulos P, Mouzaki A. 2014. Cytokines as Biomarkers of Multiple Sclerosis Disease Progression and Treatment Response to IFN β . *Mult. Scler. Int.*, art. ID 436764. <http://dx.doi.org/10.1155/2014/436764>.
91. Sazakli E, Villanueva CM, Kogevinas M, Maltezos K, Mouzaki A, Leotsinidis M. 2014. Chromium in drinking water: Association with biomarkers of exposure and effect. *Int. J. Environ. Res. Public Health*, 11(10):10125-10145. doi: 10.3390/ijerph110x0000x.
92. Mouzaki A. 2015. Stem cell transplantation (SCT) to treat severe refractory multiple sclerosis (MS). *Int. J. Transplant. Res. Med.*, 1:002e. EDITORIAL <http://clinmedjournals.org/articles/ijtrm/ijtrm-1-002e.pdf>.
93. Deraos G, Rodi M, Kalbacher H, Chatzantoni K, Karagiannis F, Synodinos L, Plotas P, Papalois A, Dimisianos N, Papathanasopoulos P, Gatos D, Tselios T, Apostolopoulos V, Mouzaki A*, Matsoukas J*. 2015. Properties of myelin altered peptide ligand cyclo(87-99)(Ala91,Ala96)MBP87-99 render it a promising drug lead for immunotherapy of Multiple Sclerosis. *Eur. J. Med. Chem.*, 101:13-23. doi: 10.1016/j.ejmech.2015.06.015 *senior authors
94. Kostopoulou ON, Magoulas GE, Papadopoulos GE, Mouzaki A, Dinos GP, Papaioannou D, Kalpaxis DL. 2015. Synthesis and evaluation of chloramphenicol homodimers: Molecular target, antimicrobial activity, and toxicity against human cells. *PLoS ONE*, 10(8):e0134526. doi: 10.1371/journal.pone.0134526
95. Mouzaki A, Rodi M, Dimisianos N, Emmanuil A, Kalavrizioti D, Lagoudaki R, Nikolaos C. Grigoriadis NC, Papathanasopoulos P. 2015. Immune parameters that distinguish multiple sclerosis patients from patients with other neurological disorders at presentation. *PLoS ONE*, 10(8):e0135434. doi: 10.1371/journal.pone.0135434
96. Mouzaki A, Garyfallou MI, Chatzantoni K. Stem cell transplantation to treat severe refractory multiple sclerosis. 2015. *Int. J. Transplant. Res. Med.*, 1:008, pp. 1-3. <http://clinmedjournals.org/articles/ijtrm/int-j-transplant-res-med-1-008.pdf>.
97. Kalavrizioti D, Gerolymos M, Rodi M, Kalliakmani P, Provatopoulou S, Eleftheriadis T, Mouzaki A, Goumenos D. 2015. T helper (Th)-cytokines in the urine of patients with primary glomerulonephritis treated with immunosuppressive drugs: can they predict outcome? *Cytokine*, 76(2):260-269. doi: 10.1016/j.cyto.2015.08.002
98. Davanos N, Panos G, Gogos CA, Mouzaki A. 2015. HIV-1 subtype characteristics of infected persons living in southwestern Greece. *HIV/AIDS-Res. Palliat. Care*, 7:277-283. *HIV AIDS (Auckl)*, 7:277-283. doi: 10.2147/HIV.S90755.
99. de Lastic AL, Rodi M, Mouzaki A. 2016. Effect of dendritic cell state and antigen-presentation conditions on resulting T-cell phenotypes and Th cytokine profiles. *Immunobiology*, 221(8):862-870. doi: 10.1016/j.imbio.2016.04.001
100. Rodi M, Dimisianos N, de Lastic AL, Sakellaraki P, Deraos G, Matsoukas J, Papathanasopoulos P, Mouzaki A. 2016. Regulatory cell populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens. *Int. J. Mol. Sci.*, 17(9):1398, pp.1-17. doi: 10.3390/ijms17091398.
101. Aggelakopoulou M, Kourepini E, Paschalidis N, Simoes DCM, Kalavrizioti D, Dimisianos N, Papathanasopoulos P, Mouzaki A, Panoutsakopoulou V. 2016. ER β -dependent direct suppression of human and murine Th17 cells and treatment of established central nervous system autoimmunity by a neurosteroid. *J. Immunol.*, 197(7):2598-2609. doi: 10.4049/jimmunol.1601038
102. Dousdampanis P, Trigka K, Mouzaki A. 2016. Tregs and Kidney: from Diabetic Nephropathy to Renal Transplantation. *World J. Transplant.*, 6(3):556-563. doi: 10.5500/wjt.v6.i3.556
103. Tsigvoulis G, Katsanos AH, Mavridis D, Grigoriadis N, Dardiotis E, Heliopoulos I, Papathanasopoulos P, Karapanayiotides T, Kilidireas C, Hadjigeorgiou GM, Voumvourakis K, HELANI (Gravanis A, Papadimitriou A, Rompos A, Mouzaki A, Karagogeos D, Kollias G, Probert L, Ioannidis P, Pelidou S-E, Tzartos S, Panoutsakopoulou V). 2016. The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials. *PLoS ONE* 11(9): e0163296. doi: 10.1371/journal.pone.0163296.
104. Panagoulas I, Georgakopoulos T, Aggeletopoulou I, Agelopoulos M, Thanos D, Mouzaki A. 2016. Transcription Factor Ets-2 Acts as a Pre-induction Repressor of Interleukin-2 (IL-2) Transcription in Naive T Helper Lymphocytes. *J. Biol. Chem.*, 291(52):26707-26721. doi: 10.1074/jbc.M116.762179

105. Triantos C, Kalafateli M, Spadidea PI, Goukos D, Koutroumpakis E, Konstantakis C, Assimakopoulos SF, Gogos C, Mouzaki A, Daikos G, Thomopoulos K. 2017. Bacterial load and cytokine profile in patients with cirrhosis following therapy with proton pump inhibitors: a prospective cohort study. *Ann. Gastroenterol.*, 30(4):450-456. doi: 10.20524/aog.2017.0142.
106. Yannakakis M-P, Simal C, Tzoupis H, Rodi M, Dargaji N, Prakash M, Mouzaki A, Platts JA, Apostolopoulos V, Tselios TV. 2017. Design and synthesis of non-peptide mimetics mapping the immunodominant myelin basic protein (MBP₈₃₋₉₆) epitope to function as T-cell receptor antagonists. *Int. J. Mol. Sci.*, 18(6):1215, pp.1-29. doi: 10.3390/ijms18061215.
107. Panagoulas I, Karagiannis F, Aggeletopoulou I, Georgakopoulos T, Argyropoulos CP, Akinosoglou K, Gogos C, Skoutelis A, Mouzaki A. 2018. Ets-2 acts as a transcriptional repressor of the human immunodeficiency virus type 1 through binding to a repressor-activator target sequence of 5'-LTR. *Front. Immunol.*, 8:1924. doi: 10.3389/fimmu.2017.01924.
108. Toumpeki C, Anastasakis D, Panagoulas I, Stamatopoulou V, Georgakopoulos T, Kallia-Raftopoulos S, Mouzaki A*, Drinas D*. 2018. Construction of an M1GS ribozyme for targeted and rapid mRNA cleavage; application on the Ets-2 oncogene. *Med. Chem.*, 14(6):604-616. doi: 10.2174/1573406414666180112115201 / *senior authors
109. Stravodimou A, Tzelepi V, Papadaki H, Mouzaki A, Georgiou S, Melachrinou M, Kourea EP. 2018. Evaluation of T lymphocyte subpopulations in Actinic Keratosis, In Situ and Invasive Squamous Cell Carcinoma of the Skin. *J. Cutan. Pathol.*, 45(5):337-347. doi: 10.1111/cup.13123
110. Psianou K, Panagoulas I, Papanastasiou AD, de Lastic AL, Rodi M, Spantidea PI, Degn SE, Georgiou P, Mouzaki A. 2018. Clinical and immunological parameters of Sjögren's syndrome. *Autoimmun. Rev.*, 17(10):1053-1064. doi: 10.1016/j.autrev.2018.05.005
111. Triantos C, Aggeletopoulou I, Kalafateli M, Spantidea PI, Vourli G, Diamantopoulou G, Tapratzi D, Michalaki M, Manolakopoulos S, Gogos C, Kyriazopoulou V, Mouzaki A, Thomopoulos K. 2018. Prognostic significance of vitamin D receptor (VDR) gene polymorphisms in liver cirrhosis. *Sci. Rep.*, 8(1):14065. doi: 10.1038/s41598-018-32482-3
112. Gioldasi S, Karvela A, Rojas-Gil AP, Rodi M, de Lastic AL, Thomas I, Spiliotis BE, Mouzaki A. 2019. Metabolic association between leptin and the corticotropin releasing hormone. *Endocr. Metab. Immune Disord. Drug Targets*, 19(4):458-466. doi: 10.2174/1871530319666190206165626
113. Marazioti A, Papadia K, Kannavou M, Spella M, Basta A, de Lastic AL, Rodi M, Mouzaki A, Samiotaki M, Panayotou G, Stathopoulos GT, Antimisariar S. 2019. Cellular Vesicles: New insights in engineering methods, interaction with cells and potential for brain targeting. *J. Pharmacol. Exp. Ther.*, 370(3):772-785. <https://doi.org/10.1124/jpet.119.257097>
114. Triantos C, Kalafateli M, Aggeletopoulou I, Diamantopoulou G, Spantidea PI, Michalaki M, Vourli G, Konstantakis C, Assimakopoulos SF, Manolakopoulos S, Gogos C, Kyriazopoulou V, Mouzaki A, Thomopoulos K. 2020. Vitamin D-related immunomodulation in patients with liver cirrhosis. *Eur. J. Gastroenterol. Hepatol.*, 32(7):867-876. doi: 10.1097/MEG.0000000000001597
115. Assimakopoulos SF, Akinosoglou K, de Lastic AL, Skintzi A, Mouzaki A, Gogos CA. 2020. The prognostic value of endotoxemia and intestinal barrier biomarker ZO-1 in bacteremic sepsis. *Am. J. Med. Sci.*, 359(2):100-107. <https://doi.org/10.1016/j.amjms.2019.10.006>
116. Karageorgiadi DM, Tsilimigras DI, Selemenakis P, Vlachou V, de Lastic AL, Rodi M, Chatziathanasiou D, Savvatakis K, Antoniou N, Deli AC, Papalambros A, Filis KA, Mouzaki A, Varvarigou A, Zografos G, Gorgoulis VG, Pateras IS, Sigala F. 2020. Conditioning attenuates kidney and heart injury in rats following transient suparenal occlusion of the abdominal aorta. *Sci. Rep.*, 10(1):5040. <https://doi.org/10.1038/s41598-020-61268-9>
117. Anastasopoulou S, Mouzaki A. 2020. The biology of SARS-CoV-2 and the ensuing COVID-19. *Achaiki Iatriki*, 39(1):29-35.
118. Davoulou P, Aggeletopoulou I, Panagoulas I, Georgakopoulos T, Mouzaki A. 2020. Transcription factor Ets-2 regulates the expression of key lymphotropic factors. *Mol. Biol. Rep.*, 47(10):7871-7881. doi: 10.1007/s11033-020-05865-x
119. Tourkochristou E, Mouzaki, A. 2021. mRNA vaccines to protect against COVID-19. *Achaiki Iatriki*, 40(1):7-10.
120. Rodi M, Georgakopoulos T, Kalogianni F, Alexandropoulou A, de Lastic AL, Panagoulas I, Mouzaki A. 2021. An in-house procedure for the isolation of total RNA for SARS-CoV-2 detection in nasopharyngeal or oropharyngeal specimens by quantitative real time PCR. *Achaiki Iatriki*, 40(1):28-33.
121. Assimakopoulos SF, Papadopolou I, Bantouna D, de Lastic AL, Maria Rodi M, Mouzaki A, Gogos CA, Zolota V, Maroulis I. 2021. Fecal microbiota transplantation and hydrocortisone

- ameliorate intestinal barrier dysfunction and improve survival in a rat model of cecal ligation and puncture-induced sepsis. *Shock*, 55(5):666-675. doi: 10.1097/SHK.0000000000001566
122. Triantos C, Aggeletopoulou I, Thomopoulos K, Mouzaki A. 2021. Vitamin D - liver disease association: Biological basis and mechanisms of action. *Hepatology*, 74(2):1065-1073. doi: 10.1002/hep.31699
 123. Tsounis EP, Tourkochristou E, Mouzaki A, Triantos C. 2021. Towards a new era of HBV therapeutics: the pursuit of functional cure. *World J. Gastroenterol.*, 27(21):2727-2757. doi: <https://dx.doi.org/10.3748/wjg.v27.i21.2727>
 124. Tourkochristou E, Triantos C, Mouzaki A. 2021. The influence of nutritional factors on immunological outcomes. *Front. Immunol.*, 12:665968. doi: 10.3389/fimmu.2021.665968
 125. Tourkochristou E, Mouzaki A. 2021. COVID-19 and the Digestive System - Pathophysiological Aspects. *Achaiki Iatriki*, 40(3):1-4.
 126. Assimakopoulos SF, Mastronikolis S, Lastic AL, Aretha D, Papageorgiou D, Chalkidi T, Oikonomou I, Triantos C, Mouzaki A, Marangos M. 2021. Intestinal barrier biomarker ZO-1 and endotoxin are increased in blood of patients with COVID-19-associated pneumonia. *In Vivo*, 35(4):2483-2488. doi:10.21873/invivo.12528
 127. Assimakopoulos SF, Aretha D, Komninos D, Dimitropoulou D, Lagadinou M, Leonidou L, Oikonomou I, Mouzaki A, Marangos M. 2021. N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study. *Infect. Dis.*, 53(11):847-854. doi: 10.1080/23744235.2021.1945675
 128. Stravodimou A, Tzelepi V, Balasis S, Georgiou S, Papadaki H, Mouzaki A, Melachrinou M, Kourea EP. 2021. PD-L1 expression, T lymphocyte subpopulations and Langerhans cells in cutaneous squamous cell carcinoma and precursor lesions. *Anticancer Res.*, 41(7):3439-3448. doi: 10.21873/anticancer.11xxx
 129. Pefani-Antimisiri K, Athanasopoulos DK, Marazioti A, Sklias K, Rodi M, de Lastic AL, Mouzaki A, Svarnas P, Antimisiri SG. 2021. Synergistic effect of cold atmospheric pressure plasma and free or liposomal Doxorubicin on melanoma cells. *Sci. Rep.*, 11:14788. <https://doi.org/10.1038/s41598-021-94130-7>
 130. Thomas I, Panagoulas I, Aggeletopoulou I, Varvarigou A, Spiliotis BE, Mouzaki A. 2021. The role of leptin in childhood immune thrombocytopenia (ITP): an anti-inflammatory agent? *Int. J. Mol. Sci.*, 22(14):7636. <https://doi.org/10.3390/ijms22147636>
 131. Tsounis EP, Mouzaki A, Triantos C. 2021. Nucleic Acid Vaccines: A taboo broken and prospect for a hepatitis B virus cure. *World J. Gastroenterol.*, 27(41):7005-7013. <https://dx.doi.org/10.3748/wjg.v27.i41.7005>
 132. Tsounis EP, Tourkochristou E, Sapsani A, Aggeletopoulou I, Lourida T, Zisimopoulos K, Tzikopoulos T, Diamantopoulou G, Tsintoni A, Thomopoulos K, Mouzaki A, Triantos C. 2022. The Role of Vitamin D Receptor Polymorphisms in the Course of Chronic Hepatitis C Infection. *Ann. Gastroenterol.*, 35(2):203-212. doi: <https://doi.org/10.20524/aog.2022.0697>
 133. Triantos C, Kalafateli M, Assimakopoulos SF, Karaivazoglou K, Mantaka A, Aggeletopoulou I, Spantidea PI, Tsiaoussis G, Rodi M, Kranidioti H, Goukos D, Manolakopoulos S, Gogos C, Samonakis DN, Daikos GL, Mouzaki A, Thomopoulos K. 2022. Endotoxin translocation and gut barrier dysfunction are related to variceal bleeding in patients with liver cirrhosis. *Front. Med.*, 9:836306. doi: 10.3389/fmed.2022.836306
 134. Tourkochristou E, Mouzaki A. 2022. Viral dynamics of the Omicron variant in COVID-19 disease. *Achaiki Iatriki*, 41(1):13-17.
 135. Triantos C, Aggeletopoulou I, Mantzaris GJ, Mouzaki A. 2022. Molecular basis of vitamin D action in inflammatory bowel disease. *Autoimmun. Rev.*, 21(8):103136. <https://doi.org/10.1016/j.autrev.2022.103136>
 136. Aggeletopoulou I, Thomopoulos K, Mouzaki A, Triantos C. 2022. Vitamin D-VDR novel anti-inflammatory molecules - new insights into their effects on liver diseases. *Int. J. Mol. Sci.*, 23(15):8465. <https://doi.org/10.3390/ijms23158465>
 137. Tourkochristou E, Mouzaki A, Triantos C. 2023. Unveiling the biological role of sphingosine 1 phosphate receptor modulators in inflammatory bowel diseases. *World J. Gastroenterol.*, 29(1):110-125. doi: 10.3748/wjg.v29.i1.110
 138. Panagoulas I, Charokopos N, Iason Thomas I, Spantidea PI, de Lastic AL, Rodi M, Anastasopoulou S, Aggeletopoulou I, Lazaris C, Karkoulas K, Leonidou L, Georgopoulos NA, Markou KB, Mouzaki A. 2023. Shifting gears: study of immune system parameters of male habitual marathon runners. *Front. Immunol.*, 13:1009065. doi: 10.3389/fimmu.2022.1009065

139. Aggeletopoulou I, Mouzaki A, Thomopoulos K, Triantos C. 2023. MiRNA molecules - late breaking treatment for inflammatory bowel diseases? *Int. J. Mol. Sci.*, 24(3):2233. <https://doi.org/10.3390/ijms24032233>
140. Aggeletopoulou I, Marangos M, Assimakopoulos SF, Mouzaki A, Thomopoulos K, Triantos C. 2023. Vitamin D and Microbiome: Molecular Interaction in Inflammatory Bowel Disease Pathogenesis. *Am. J. Pathol.*, 193(6):656-668. <https://doi.org/10.1016/j.ajpath.2023.02.004>
141. Eleftheriotis G, Tsounis EP, Aggeletopoulou I, Dousdampanis P, Triantos C, Mouzaki A, Marangos M, Assimakopoulos SF. 2023. Alterations in gut immunological barrier in SARS-CoV-2 infection and their prognostic potential. *Front. Immunol.*, 14:1129190. doi: 10.3389/fimmu.2023.1129190
142. Akinosoglou K, Kolosaka M, Schinas G, De Lastic AL, Antonopoulou S, Perperis A, Marangos M, Mouzaki A, Gogos C. 2023. Association of Antiretroviral Therapy with Platelet Function and Systemic Inflammatory Response in People Living with HIV: A Cross-Sectional Study. *Microorganisms*, 11(4):958. doi: 10.3390/microorganisms11040958
143. Tourkochristou E, Mouzaki A, Triantos C. 2023. Gene polymorphisms and biological effects of vitamin D receptor on nonalcoholic fatty liver disease development and progression. *Int. J. Mol. Sci.*, 24:8288. doi: 10.3390/ijms24098288
144. Vinni E, Karaivazoglou K, Tourkochristou E, Tsounis E, Kalogeropoulou M, Konstantopoulou G, Lourida T, Kafentzi T, Lampropoulou E, Rodi M, Aggeletopoulou I, Diamantopoulou G, Theocharis G, Thomopoulos K, Gourzis P, Mouzaki A, Triantos C. 2023. Alexithymic characteristics and interoceptive abilities are associated with disease severity, CRP and cytokine levels in inflammatory bowel disease patients. *Ann. Gastroenterol.* 36(4):412-422. doi: 10.20524/aog.2023.0813
145. Anastasopoulou S, Georgakopoulos T, Mouzaki A. 2023. HIV-1 transcriptional activator Tat inhibits IL-2 expression by preventing the presence of Pol II on the IL2 promoter. *Biomolecules*, 13(6):881. <https://doi.org/10.3390/biom13060881>
146. Aggeletopoulou I, Tsounis EP, Mouzaki A, Triantos C. 2023. Exploring the role of vitamin D and the vitamin D receptor (VDR) in the composition of the gut microbiota. *Front. Biosci. (Landmark Ed)*, 28(6):116. doi: 10.31083/j.fbl2806116
147. Tsounis EP, Aggeletopoulou I, Mouzaki A, Triantos C. 2023. Creeping fat in the pathogenesis of Crohn's disease: an orchestrator or a silent bystander? *Inflamm. Bowel Dis.*, 29(11):1826-1836. doi: 10.1093/ibd/izad095
148. Aggeletopoulou I, Tsounis EP, Mouzaki A, Triantos C. 2023. Creeping fat in Crohn's disease – Surgical, histological, and radiological approach. *J. Pers. Med.*, 13(7):1029. <https://doi.org/10.3390/jpm13071029>
149. Akwii RG, Lamprou M, Georgomanoli M, Plevriti A, Marazioti A, Mouzaki A, Mattheolabakis G, Mikelis CM. 2023. Murine dermal lymphatic endothelial cell isolation. *J Vis Exp.*, 197. doi: 10.3791/65393.
150. Tourkochristou E, Tsounis EP, Tzoupis H, Aggeletopoulou I, Tsintoni A, Lourida T, Diamantopoulou G, Zisimopoulos K, Kafentzi T, de Lastic AL, Rodi M, Tselios T, Thomopoulos K, Mouzaki A*, Triantos C*. 2023. The influence of single nucleotide polymorphisms on vitamin D receptor protein levels and function in chronic liver disease. *Int. J. Mol. Sci.*, 24(14):11404. <https://doi.org/10.3390/ijms241411404> *senior authors
151. Schinas G, Skintzi K, De Lastic AL, Rodi M, Gogos C, Mouzaki A, Akinosoglou K. 2023. Patterns, Cost, and Immunological Response of MDR vs. Non MDR-Bacteremia: A Prospective Cohort Study. *Pathogens*, 12(8):1044. doi: 10.3390/pathogens12081044
152. Dousdampanis P, Mouzaki A, Trigka K, Stefanidis I, Galanopoulos KE, Siavelis IS, Stathopoulou D, Assimakopoulos S. 2023. Kidney issues associated with COVID-19 disease. *Encyclopedia*, 3(3):1085-1104. <https://doi.org/10.3390/encyclopedia3030079>
153. Boulrieris S, Zampakis P, Panagoulas I, Mouzaki A, Constantoyannis C, Theofanopoulos A, Panagiotopoulos V. 2023. Intraluminal assessment of inflammatory factors in patients with intracranial aneurysms. *Acta Neurochir.*, 165(12):3685-3695. <https://doi.org/10.1007/s00701-023-05851-9>
154. Gakis G, Angelopoulos I, Panagoulas I, Mouzaki A. 2024. Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation. *Autoimmun. Rev.*, 23(2):103480. <https://doi.org/10.1016/j.autrev.2023.103480>
155. Koufou EE, Assimakopoulos SF, Bosgana P, de Lastic AL, Grypari MI, Georgopoulou GA, Antonopoulou S, Mouzaki A, Kourea EP, Thomopoulos K, Davlourous P. 2024. Altered expression

- of intestinal tight junction proteins in heart failure patients with reduced or preserved ejection fraction: a pathogenetic mechanism of intestinal hyperpermeability. *Biomedicines*, 12(1):160. <https://doi.org/10.3390/biomedicines12010160>
156. Georgopoulou GA, Papasotiriou M, Bosgana P, de Lastic AL, Koufou EE, Papachristou E, Goumenos DS, Davlouros P, Kourea E, Zolota V, Thomopoulos K, Mouzaki A, Assimakopoulos SF. 2024. Altered expression of intestinal tight junctions in patients with chronic kidney disease: a pathogenetic mechanism of intestinal hyperpermeability. *Biomedicines*, 12(2):368. <https://doi.org/10.3390/biomedicines12020368>
 157. Rodi M, de Lastic AL, Panagoulas I, Aggeletopoulou I, Kelaidonis K, Matsoukas J, Apostolopoulos V, Mouzaki A. 2024. Myelin Oligodendrocyte Glycoprotein (MOG)35–55 Mannan Conjugate Induces Human T-cell Tolerance and Can Be Used as a Personalized Therapy for Multiple Sclerosis. *Int. J. Mol. Sci.*, 25(11):6092. <https://doi.org/10.3390/ijms25116092>
 158. Oikonomou I, Papageorgiou A, de Lastic AL, Moulas A, Georgopoulou GA, Mouzaki A, Koufou EE, Tsigkas G, Gogos C, Davlouros P, Assimakopoulos SF. 2024. Gut barrier dysfunction, endotoxemia and inflammatory response in STEMI patients and effect of primary PCI. *Am. J. Med. Sci.*, 368(5):485-493. <https://doi.org/10.1016/j.amjms.2024.07.004>
 159. Polyzou E, Schinas G, Bountouris P, Georgakopoulou D, de Lastic AL, Parthymou A, Gogos C, Kyriazopoulou V, Mouzaki A, Theodoropoulou A, Akinosoglou K. 2024. Prolactin role in COVID-19 and its association with the underlying inflammatory response. *Int. J. Mol. Sci.*, 25(22):11905. doi: 10.3390/ijms252211905
 160. Dousdampanis P, Aggeletopoulou I, Mouzaki A. 2025. The role of M1/M2 macrophage polarization in the pathogenesis of obesity-related kidney disease and related pathologies. *Front. Immunol.*, 15:1534823. doi: 10.3389/fimmu.2024.1534823
 161. Kalogeropoulou M, Karaivazoglou K, Konstantopoulou G, Vinni E, Sotiropoulos C, Tourkochristou E, Aggeletopoulou I, Lourida T, Labropoulou E, Diamantopoulou G, Mouzaki A, Assimakopoulos K, Gourzis P, Thomopoulos K, Theocharis G, Triantos C. 2025. The impact of group cognitive behavioral psychotherapy on disease severity and psychosocial functioning in patients with inflammatory bowel disease: a randomized controlled study. *J. Crohns Colitis*, 19(3):jjae144. doi: 10.1093/ecco-jcc/jjae144.